Nucleus Network

Nucleus Network is a clinical trial organization that specializes in early-phase clinical studies, particularly Phase 1 trials, catering to pharmaceutical and biotechnology companies globally. Nucleus Network Pty Ltd, dba Nucleus Network founded in 1993 and headquartered in Melbourne, Australia, focuses on conducting early-stage clinical trials. The company is led by its CEO Teena Pisarev as of April 2026. Nucleus Network, LLC was acquired by Blackstone Group from Crescent Capital Partners in October 2021, marking a strategic pivot to enhance its growth.

The Company expanded its operations to key cities such as Brisbane and Minneapolis, further solidifying its presence in both Australia and the USA. Nucleus Network specializes in conducting early-stage clinical trials, particularly Phase 1 trials, for pharmaceutical and biotechnology companies. They manage a range of clinical studies lasting from two days to several weeks, targeting both healthy volunteers and patients with various medical conditions. Their facilities are equipped to handle complex clinical pharmacology studies including hepatic and renal trials.

The organization serves a diverse clientele, including leading pharmaceutical firms, and the data generated supports regulatory filings with agencies like the FDA, EMA, PMDA, and Health Canada. In the most recent year, Nucleus Network reported revenue of USD 34. 10 mn and an EBITDA of USD 8. 90 mn.

The company's revenue model is primarily based on B2B transactions with pharmaceutical and biotechnology clients for conducting specific clinical trials under fixed contracts, reflecting the complexity and duration of the services provided. Following its acquisition by Blackstone Group in October 2021, Nucleus Network plans to utilize the support from its new parent company to drive its next phase of growth. While specific new products in development have not been disclosed, the company aims to expand its reach within existing markets and explore new geographic regions to better serve its clients. The acquisition aligns with Nucleus Network's strategy to enhance its operational capabilities and broaden its service offerings in the clinical trial landscape.